Collegium Pharmaceutical, Inc. Accounts Receivable
Collegium Pharmaceutical, Inc. (COLL) had Accounts Receivable of $285.10 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $285.10M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $228.76M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $211.33M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $233.95M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $285.10M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $228.76M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $211.33M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $233.95M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $213.02M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $228.71M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $228.54M 10-K · filed 2026-02-26 |
| 2024-09-30 | $228.46M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $183.85M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $174.69M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $179.53M 10-K · filed 2025-02-27 |
| 2023-09-30 | $181.85M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $167.48M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $179.13M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $183.12M 10-K · filed 2024-02-22 |
| 2022-09-30 | $195.40M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $197.50M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $166.34M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $105.84M 10-K · filed 2023-02-23 |
| 2021-09-30 | $149.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $90.10M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $93.16M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $83.32M 10-K · filed 2022-02-24 |
| 2020-09-30 | $76.47M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $81.19M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $85.43M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $72.95M 10-K · filed 2021-02-25 |
| 2019-09-30 | $84.38M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $81.28M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $85.14M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $77.95M 10-K · filed 2020-02-27 |
| 2018-09-30 | $66.53M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $68.38M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $66.04M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $9.97M 10-K · filed 2019-02-27 |
| 2017-09-30 | $5.82M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $4.88M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $3.35M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $2.13M 10-K · filed 2018-03-07 |
| 2016-09-30 | $1.68M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $2.95M 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |